US regulator investigates tumour risk in children given Novartis gene therapy
GlobeAlert Desk · curated from South China Morning Post · North America
The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated with Novartis’ gene therapy Zolgensma. The Swiss drug maker earlier in the day disclosed two cases in which tumours in children showed evidence of being linked to its gene therapy drug used to treat patients less than two years old with spinal muscular atrophy. Novartis said that it had received nine reports overall of tumours in patients...
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
What the desk knows about this story
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Single-source so far. Treat details as unconfirmed until more publishers report.
Not flagged as developing.
- Protest activity (130 reports)Protests · · 5m ago
- Conflict activity (123 reports)Conflict Events · · 20m ago
- Cyber activity (106 reports)Cyber Threats · · 48m ago